SCHEMBL23360640

SCHEMBL23360640

Cc1cccc2c(CNC(=O)O)c[nH]c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.55
MAPT P10636 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
BRPF1 P55201 1/20 0.53
NR4A2 P43354 1/20 0.52
SOS2 Q07890 1/20 0.52
POLB P06746 1/20 0.50
RAB9A P51151 1/20 0.50
HTT P42858 1/20 0.48
FTO Q9C0B1 1/20 0.47
TRIM24 O15164 1/20 0.46
TRIM33 Q9UPN9 1/20 0.46
NR3C1 P04150 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
PCSK9 Q8NBP7 1/20 0.45
MTNR1A P48039 1/20 0.44
MTNR1B P49286 1/20 0.44
ITGB2 P05107 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3279608 0.90 BRPF1 (0.55) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL23370445 0.83 NR4A2 (0.48) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL6284097 0.81 HTR2A (0.58) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL21392080 0.81 CHRNB2 (0.47) SMN1; SMN2HTTMTNR1AMTNR1BCNR2
SCHEMBL10678420 0.79 HTR2A (0.63) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL8297888 0.79 HTR2A (0.67) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL6920054 0.78 MTNR1A (0.70) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL3611008 0.77 HTR2A (0.60) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL27911678 0.77 HTR2A (0.69) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL24328921 0.77 SMN1; SMN2 (0.61) HTR2AMAPTSMN1; SMN2NPSR1BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210147405-A1 BICYCLIC HETEROAROMATIC UREA OR CARBAMATE COMPOUNDS FOR USE IN THERAPY EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2021-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147405-A1 BICYCLIC HETEROAROMATIC UREA OR CARBAMATE COMPOUNDS FOR USE IN THERAPY HIF1A, HIF1AN, EGLN3 HTR2A 3750/4885MAPT 1519/4885SMN1; SMN2 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.